Introduction
Sickle cell disease (SCD) is a hematologic disorder caused by a single nucleotide mutation in the beta globin gene. Under hypoxic conditions, the mutation leads to abnormal polymerization of hemoglobin tetramers. Aggregation of abnormally large hemoglobin polymers results in the formation of sickle red blood cells that are susceptible to hemolysis, adhere to the endothelium, and form aggregates with leukocytes and platelets 1 . These processes result in the two primary pathologies of SCD: hemolytic anemia and vaso-occlusive crises 2, 3 . Furthermore, SCD is also associated with a chronic activation of coagulation and vascular inflammation.
Despite the well-documented hypercoagulable state of SCD, little is known about the contribution of coagulation to the pathology of the disease. Clinical studies investigating the use of warfarin 4 , acenocoumarol 5 and heparin 6 in acute pain crises in sickle cell patients were inconclusive; however, these studies were performed on a small number of patients, lacked placebo controls and used pain crises as the only clinical endpoint 7 .
Notably, the only adequately powered and placebo-controlled study to examine the effect of the low molecular weight heparin tinzaparin demonstrated a significant reduction in the duration of a painful crisis and hospital stay 8 , suggesting that anticoagulants might be beneficial in SCD.
In SCD, increased expression of tissue factor (TF) has been demonstrated in both leukocytes and endothelial cells (ECs) 9, 10 . We and others recently demonstrated that inhibition of TF inhibited activation of coagulation and attenuated the enhanced thrombosis in cerebral microvessels in sickle mice 11, 12 . Importantly, we demonstrated that inhibition of TF also reduced plasma levels of interleukin-6 (IL-6) and soluble VCAM-1 (sVCAM-1) as well as reduced local lung inflammation measured by tissue levels of myeloperoxidase (MPO). These data indicate that TF not only promotes activation of coagulation but also contributes to chronic vascular inflammation in a mouse model of SCD 11 . Moreover, we have shown that EC-specific deletion of the TF gene significantly reduced plasma levels of IL-6 without affecting activation of
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Coagulation proteases, such as FXa and thrombin, can induce multiple cellular effects via activation of protease activated receptors (PARs). PARs are the family of G-protein coupled receptors that are activated by proteolytic cleavage. PAR-1 is activated by various proteases, including FXa and thrombin, whereas PAR-2 is activated by the TF:FVIIa complex, FXa, as well as other proteases [13] [14] [15] [16] . It has been demonstrated that coagulation protease-dependent activation of PARs contributes to inflammation in many vascular disorders [17] [18] [19] .
In this study, we investigated the mechanism by which two coagulation proteases, FXa and thrombin, contribute to the vascular inflammation in sickle cell mice. Mice were treated with either the direct FXa inhibitor rivaroxaban or the direct thrombin inhibitor dabigatran. We also determined the role of non-hematopoietic PAR-1 and PAR-2 by transplanting bone marrow (BM) from sickle mice into PAR-1 or PAR-2 deficient mice.
Our results demonstrate that FXa and thrombin differentially contribute to the vascular inflammation in a mouse model of SCD.
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Methods

Mice
We used the Berkeley (BERK) mouse model of SCD PAR-2. Generation of PAR-1 and PAR-2 deficient mice was previously described 21, 22 .
They were backcrossed to a C57Bl/6J background for 10 generations and experimental animals were generated by intercrossing PAR- . In similar studies, C57Bl/6J mice were fed with placebo or rivaroxaban (Janssen Pharmaceuticals, Bayer AG) at 0.0125, 0.2 or 0.4 mg/g chow (Dyets Inc, Bethlehem, PA) for 10 days. Blood was collected in the morning, and prothrombin time (PT) was assessed in plasma as described below. To measure the plasma concentration of rivaroxaban in mice, the PT was compared to a standard curve generated by measuring the PT of normal mouse plasma containing known concentrations of rivaroxaban. We assumed that plasma concentrations of dabigatran and rivaroxaban would be at the peak in the morning since mice are nocturnal.
Saphenous vein bleeding model
Eight week old male C57Bl/6J mice were fed chow containing placebo, dabigatran (10 mg/g chow) or rivaroxaban (0.4 mg/g chow) for 5 days. On the morning of the last day of treatment, the level of anticoagulation was determined using the saphenous vein bleeding model as previously described 24 .
Dabigatran and rivaroxaban treatment and sample collection
Once the optimal doses of dabigatran and rivaroxaban were determined, four month old BERK AA and BERK SS mice were fed chow containing placebo, dabigatran (10 mg/g chow) or rivaroxaban (0.4 mg/g chow) ad libitum for 10 days. Four months after BM transplantation, or 10 days after feeding with chow containing anticoagulants, mice were anesthetized with isoflurane. Blood was drawn from the inferior vena cava into 3.4% sodium citrate (final ratio of 9:1) and plasma was stored at -80˚C. The entire left lung was collected for histological analysis and remaining tissue was snap frozen in liquid nitrogen and stored at -80˚C.
Analysis of hematologic profile, PT, aPTT, TAT, sVCAM-1 and IL-6
Blood cell count and hematologic profile were determined using the automatic HEMAVET system (Drew Scientific, Inc. 
Analysis of MPO in lung tissue
Protein was isolated from lung as previously described 11 Figure   1D ). The 0.4 mg/g chow dose was used for subsequent studies. We observed no spontaneous bleeding in mice treated with 10 mg/g dabigatran or 0.4 mg/g rivaroxaban.
To directly compare the levels of anticoagulation after dabigatran and rivaroxaban treatment, wild type mice were treated with dabigatran or rivaroxaban for five days ad 1 0 libitum, and hemostasis time was determined using a saphenous vein bleeding model 24 .
Since mice are nocturnal, all measurements were performed in the morning, to minimize the variability in the plasma drug levels due to differences in chow consumption. Both rivaroxaban and dabigatran significantly prolonged hemostasis time compared to untreated mice; dabigatran-treated mice had a significantly longer mean hemostasis time than rivaroxaban-treated mice ( Figure 1E ). In addition, the number of clots formed during 30 minutes was significantly reduced in mice fed with chow containing rivaroxaban and dabigatran compared to mice fed with control chow, and dabigatran treatment had a significantly stronger effect compared to rivaroxaban treatment ( Figure   1F ). These data indicate that the dose of dabigatran used for the study had a more potent anticoagulant effect compared to the dose of rivaroxaban.
Effect of thrombin inhibition on vascular inflammation in SCD
BERK SS mice had significantly lower RBC counts, hemoglobin levels, and hematocrits compared to BERK AA controls; thrombin inhibition with dabigatran had no effect on these parameters indicating that thrombin inhibition does not affect hemolysis of sickle RBCs (Table 1) . There was also a significant increase in white blood cell counts in BERK SS mice that was not affected by thrombin inhibition (Table 1) . Dabigatran prolonged aPTT in both BERK AA and BERK SS mice compared to mice on placebo chow ( Figure 2A ). There was a significant increase in plasma TAT levels in BERK SS mice compared to BERK AA controls that was attenuated with dabigatran treatment ( Figure   2B ). BERK SS mice had elevated plasma levels of IL-6 and sVCAM-1 compared to BERK AA controls; however, thrombin inhibition had no effect on these parameters ( Figure 2C-D) . Importantly, thrombin inhibition significantly attenuated the increase in MPO levels ( Figure 2E ) and the number of neutrophils observed in the lungs of BERK SS mice ( Figure 2 F-G). These data indicate that TF-dependent thrombin generation has no effect on systemic inflammation but does contribute to local inflammation in the lung via a mechanism involving neutrophil recruitment.
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Role of non-hematopoietic cell PAR-1 on vascular inflammation in SCD
To determine if the thrombin-mediated effect in the lung was PAR-1 dependent, we generated sickle cell mice lacking PAR-1 expression on all non-hematopoietic cells.
PAR-1 +/+ and PAR-1 -/-mice transplanted with BERK BM had significantly decreased red blood cell counts and hematocrits compared to mice transplanted with WT BM , indicating that deletion of PAR-1 from non-hematopoietic cells has no effect on anemia in sickle mice ( Table 2) . We also observed an increase in the total number of white blood cells in BERK BM mice; deletion of PAR-1 from non-hematopoietic cells had no effect on these parameters ( Table 2) 
Effect of FXa inhibition on vascular inflammation in SCD
FXa inhibition had no effect on markers of anemia in BERK SS mice, nor did it affect leukocytosis ( Table 2) . Rivaroxaban significantly prolonged PT in both BERK AA and BERK SS mice compared to mice on placebo chow ( Figure 4A) . Furthermore, the increase in plasma TAT levels observed in BERK SS mice was attenuated by rivaroxaban ( Figure 4B ) whereas increased levels of sVCAM-1 were not affected ( Figure 4C ).
Interestingly, FXa inhibition abolished the increase in plasma IL-6 in BERK SS mice ( Figure 4D ). We also observed a significant increase in MPO levels in the lungs of BERK SS mice compared to BERK AA mice fed with control chow ( Figure 4E ). In contrast,
we did not observe a significant increase in MPO levels in the lung of BERK SS mice fed with chow containing rivaroxaban. Consistent with this, there were significantly more Figure 4F ).
Role of non-hematopoietic cell PAR-2 on vascular inflammation in SCD
Next we determined if the pro-inflammatory effect of FXa in sickle cell mice is due to activation of PAR-2 on non-hematopoietic cells. PAR-2 +/+ and PAR-2 -/-mice were lethally irradiated and transplanted with WT BM or BERK BM . As expected, reconstitution with BM from BERK mice significantly decreased RBC counts, hemoglobin and hematocrit in PAR-2 +/+ mice, and deletion of PAR-2 from non-hematopoietic cells had no effect on these parameters (Table 3) . Interestingly, we observed a significant decrease in neutrophil numbers in PAR-2 -/-sickle mice compared to sickle PAR-2 +/+ controls ( Table 3) .
PAR-2 +/+ mice transplanted with BERK BM had significantly increased plasma TAT, sVCAM-1 and IL-6 levels ( Figure 5A-C) . Deletion of PAR-2 from non-hematopoietic cells had no effect on TAT or sVCAM-1, but dramatically reduced the increase in plasma levels of IL-6 in sickle mice ( Figure 5A -C). These data indicate that PAR-2 contributes to systemic inflammation. Furthermore, PAR-2 deletion from nonhematopoietic cells attenuated the increase in MPO levels ( Figure 5D ) and the number of neutrophils in the lungs of BERK BM mice ( Figure 5E ). . Furthermore, PAR-2 contributed to the neutrophilia, which is commonly observed in both sickle cell patients and animal models of SCD 11, 37 .
Sickle cell mice lacking PAR-2 in all non-hematopoietic cells had significantly reduced number of circulating neutrophils compared to PAR-2 proficient sickle cell mice.
Interestingly, neutrophilia was not affected by inhibition of TF 11 , which warrants further studies to investigate both anti-coagulant and possibly anti-inflammatory effects of exogenous APC administration.
Pulmonary hypertension (PH) is a common clinical complication of SCD, but the
etiology has yet to be defined 43, 44 . Proposed mechanisms include vasoconstriction and endothelial dysfunction due to NO depletion 42, 43 , or the hypercoagulable state and chronic inflammation 3, [45] [46] [47] . Indeed, SCD patients with PH have higher levels of coagulation and inflammation biomarkers compared to the sickle cell patients without PH 48 . There is an emerging concept that inflammation is an important proximal mediator 1 6 in the generation of PH in the general population 49 . Recent studies demonstrated that rivaroxaban treatment, as well as PAR-2 or IL-6 deficiency, attenuates PH in animal models [50] [51] [52] . Also, there is at least one case report in which PH improved in a patient treated with an IL-6 receptor blocking antibody 53 . Therefore, our data from PAR-2 deficient mice and rivaroxaban experiments imply that targeting FXa mediated PAR-2 activation may reduce IL-6 expression and potentially attenuate PH in SCD.
ECs are chronically activated in SCD, in part due to increased adherence of sickle RBCs and activated leukocytes, as well as high levels of cell-free hemoglobin and heme in the blood 42 . We previously found that inhibition of TF with a rat monoclonal antibody called 1H1 attenuates EC activation in sickle cell mice, as measured by plasma levels of sVCAM-1
11
; however deletion of TF from ECs 11 or low levels of TF in all nonhematopoietic cells (data not shown) had no effect on plasma levels of sVCAM-1. In the present study, neither FXa nor thrombin inhibition had any effect on this marker of EC activation in BERK SS mice. Moreover, non-hematopoietic PAR-1 and PAR-2 also did not affect plasma levels of sVCAM-1 in sickle cell mice. These data suggest that the TF- SCD is one of a few pathological conditions in which TF expression is upregulated not only on leukocytes but also on ECs. Our data indicate that TF expressed by different cell types has specific roles in the pathology of the disease ( Figure 6 ). We propose that EC TF does not contribute to the activation of coagulation in sickle cell disease but instead, contributes to systemic inflammation mediated by FXa dependent activation of PAR-2 on ECs. The fact that deletion of TF from ECs 11 or low levels of TF in all non- or BERK (N=8-12) mice. Asterisks directly above the bars indicate statistically significant difference between BERK BM mice compared to WT BM mice within the same PAR-2 genotype.
*p<0.05, ** p<0.01, and *** p<0.001. 
